On August 6, 2026 BlossomHill Therapeutics, Inc., ("BlossomHill Therapeutics"), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop innovative small molecule medicines for the treatment of cancer, reported the pricing of its upsized initial public offering of 9,375,000 shares of common stock at a price to the public of $16.00 per share. The gross proceeds to BlossomHill Therapeutics from the offering, before deducting underwriting discounts and commissions and offering expenses payable by BlossomHill Therapeutics, are expected to be $150.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. In addition, BlossomHill Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by BlossomHill Therapeutics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The shares are expected to begin trading on The Nasdaq Global Select Market on August 7, 2026, under the ticker symbol "BLSM." The offering is expected to close on August 10, 2026, subject to the satisfaction of customary closing conditions.

J.P. Morgan, Leerink Partners and Guggenheim Securities are acting as lead book-running managers for the offering. LifeSci Capital and H.C. Wainwright & Co. are acting as joint book-running managers for the offering.

Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on August 6, 2026. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities. When available, copies of the final prospectus relating to the initial public offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected] and [email protected]; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105 or by email at [email protected]; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave., 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected].

This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

(Press release, BlossomHill Therapeutics, AUG 6, 2026, View Source [SID1234669838])

On August 6, 2026 OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, reported financial results for the three and six months ended June 30, 2026, provided operating and partner program progress, and updated 2026 financial guidance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to report a strong quarter and to increase our revenue and cash outlook for 2026 based on continued momentum in our business. Recent updates from partner programs have been very encouraging with important advancements in clinical development," stated Matt Foehr, Chief Executive Officer of OmniAb. "We continue to efficiently leverage and expand the reach of our core and highly differentiated discovery technologies, as we also focus on our promising xPloration platform. We recently expanded our executive leadership with the addition of Chief Operating Officer Amechi Nwachuku, who has quickly integrated into our team to drive and strengthen this area. We believe we’re well positioned to accelerate growth, and we look forward to providing business updates and technology highlights and plans at our October Investor and Analyst Day."

Second Quarter 2026 Financial Results

Revenue for the second quarter of 2026 was $13.4 million, compared with $3.9 million in the prior-year period, with the increase driven primarily by milestone revenue. Service revenue increased primarily due to the commencement of new ion channel programs, and xPloration revenue increased on higher instrument sales and related consumables.

Cost of xPloration revenue was $0.6 million for the second quarter of 2026, compared with $0.3 million for the same period in 2025. The increase was due to increased instrument and consumable sales. Research and development expense was $9.6 million for the second quarter of 2026, compared with $10.9 million for the same period in 2025, with the decrease due to lower personnel expense related to share-based compensation and salary expense and lower facility-related costs. General and administrative expense was $6.7 million for the second quarter of 2026, compared with $7.7 million for the same period in 2025, with the decrease primarily due to lower personnel expense related to share-based compensation and salary expense and lower professional fees.

Amortization of intangibles decreased to $3.1 million for the second quarter of 2026, compared with $3.2 million for the same period in 2025. Other operating expense (income) increased to $0.2 million for the second quarter of 2026 from ($1.9) million for the same period in 2025, primarily as a result of a net $2.0 million one-time gain from the sale of a small-molecule program in the second quarter of 2025.

Total costs and operating expenses were $20.1 million for the second quarter of 2026, flat with $20.1 million for the same period in 2025.

Cash costs and operating expenses were $13.3 million for the second quarter of 2026, compared with $11.9 million for the same period in 2025 (see note regarding "Use of Non-GAAP Financial Measure" below for further discussion of this non-GAAP measure).

Net loss for the second quarter of 2026 was $5.9 million, or $0.05 per share, compared with a net loss of $15.9 million, or $0.15 per share, for the same period in 2025.

Year-to-Date Financial Results

Revenue for the first half of 2026 was $27.8 million, compared with $8.1 million for the same period in 2025, with the increase primarily related to milestone revenue. Service revenue increased primarily due to the commencement of new ion channel programs, and xPloration revenue increased on higher instrument sales and related consumables.

Cost of xPloration revenue was $0.6 million for the first half of 2026, compared with $0.3 million for the same period in 2025. The increase was due to increased instrument and consumable sales. Research and development expense was $19.2 million for the first half of 2026, compared with $23.5 million for the same period in 2025, with the decrease due to lower personnel expense related to share-based compensation and salary expense, lower external expenses associated with legacy small-molecule ion channel programs and lower facility-related costs. General and administrative expense was $13.3 million for the first half of 2026, compared with $15.6 million for the same period in 2025, with the decrease primarily due to lower personnel expense related to share-based compensation and salary expense and lower professional fees.

Amortization of intangibles increased to $9.1 million for the first half of 2026, compared with $6.5 million for the same period in 2025, primarily due to a $2.9 million non-cash impairment related to the discontinuation of certain legacy small-molecule ion channel programs recorded in the first quarter of 2026.

Other operating expense (income) for the first half of 2026 was $0.1 million compared to ($2.7) million for the same period in 2025. The prior-year period included a net $2.0 million one-time gain from the sale of a small-molecule program in the second quarter of 2025.

Total costs and operating expenses were $42.3 million for the first half of 2026, compared with $43.1 million for the same period in 2025.

Cash costs and operating expenses were $25.5 million for the first half of 2026, compared with $26.6 million for the same period in 2025 (see note regarding "Use of Non-GAAP Financial Measure" below for further discussion of this non-GAAP measure).

Net loss for the first half of 2026 was $13.6 million, or $0.11 per share, compared with a net loss of $34.1 million, or $0.32 per share, for the same period in 2025.

As of June 30, 2026, OmniAb had cash, cash equivalents and short-term investments of $52.0 million.

2026 Financial Guidance

OmniAb revises 2026 financial guidance and now expects revenue to be in the range of $32 million to $36 million, versus $28 million to $33 million previously, and costs and operating expenses to be in the range of $84 million to $88 million, versus $83 million to $88 million previously. Cash costs and operating expenses are expected to be in the range of $51 million to $55 million, versus $50 million to $55 million previously (see note regarding "Use of Non-GAAP Financial Measure" below for further discussion of this non-GAAP measure). The Company now expects to end the year with cash and cash equivalents in the range of $37 million to $41 million, versus $33 million to $38 million previously. The full-year 2026 effective tax rate is expected to be approximately 0%.

Second Quarter 2026 and Recent Business Highlights

During the second quarter of 2026, OmniAb entered into new license agreements with EnRosa Therapeutics and argenx. As of June 30, 2026, the Company had 110 active partners and 425 active programs, including 34 OmniAb-derived programs in clinical development or being commercialized.

Business and partner highlights from the second quarter of 2026 and recent weeks included the following:

JNJ-5322

Ramantamig (JNJ-79635322), a tri-specific antibody targeting (BCMA x GPRC5D x CD3), has advanced to Phase 3 from Phase 1 clinical trials. The Phase 3 study is randomized study comparing JNJ-79635322 and an anti-BCMAxCD3 bispecific antibody in participants with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy including a PI, an IMiD, and an anti CD38 antibody.
Precemtabart tocentecan (M9140)

Merck KGaA, announced the first patient has been dosed in the Phase 3 PROCEADE-CRC-03 trial evaluating precemtabart tocentecan, a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer based on Phase 1 data.
The Phase 3 study will assess the efficacy and safety of precemtabart tocentecan, alone or with bevacizumab, in patients with metastatic colorectal cancer who are intolerant- or refractory-to, or progressed after, systemic therapies.
Phase 1 data from the PROCEADE-CRC-01 study showed predictable and manageable safety in more than 100 patients with heavily pretreated metastatic colorectal cancer. At the recommended dose for Phase 3 development (2.8 mg/kg Q3W; n=29), confirmed objective response rate was 20.7% (95% CI: 8.0, 39.7), median PFS was 6.9 months (95% CI: 4.4, 9.5), and median OS was not reached after a median follow-up of 13.1 months (95% CI: 8.7, NE).
TEV- ‘408

Teva Pharmaceuticals announced plans for its TEV-’408, an investigational anti-interleukin-15 monoclonal antibody, to advance into a Phase 2b study in vitiligo in the fourth quarter of 2026 following encouraging results from an ongoing Phase 1b, open-label study in adults with active or stable non-segmental vitiligo (NSV).
Topline results in Phase 1b trial evaluating TEV-‘408 for vitiligo showed improvements in skin pigmentation in patients with active or stable NSV. TEV-’408 was well-tolerated with no safety signals observed. At baseline, 66% of enrolled participants had vitiligo affecting more than 10% of body surface area, representing a population with limited treatment options. At week 24, in evaluable participants, nearly 75% of patients reported improvement in facial vitiligo, with half reporting "much" or "very much" improved, 42% achieved F-VASI50 and 21% achieved F-VASI75, 55% of patients reported improvement in total body vitiligo, and 7% achieved T-VASI50.
Teva Pharmaceuticals and Royalty Pharma entered into a funding agreement of up to $500 million to accelerate the clinical development of TEV-‘408 for vitiligo.
Topline results of the Phase 2a trial evaluating TEV-‘408 for celiac disease continue to be expected in the second half of 2026.
IMVT-1402

Immunovant announced preliminary week 16 IMVT-1402 results in the difficult-to-treat rheumatoid arthritis trial that showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70.
Immunovant’s development plans for IMVT-1402 remain on track across all six announced indications. They expect to provide further updates on the potentially registrational IMVT-1402 difficult-to-treat rheumatoid arthritis program and report topline data from the proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus in the second half of calendar year 2026. In calendar year 2027, topline data are anticipated for the potentially registrational trials evaluating IMVT-1402 in Graves’ disease and myasthenia gravis. Topline data are expected to follow in calendar year 2028 for the potentially registrational trials of IMVT-1402 in chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease.
BI 3802876

Boehringer Ingelheim has commenced its Phase 2a double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 3802876 in participants with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH). The study is to evaluate BI 3802876 tolerance and dose response in MASH patients.
Sugemalimab

Arrotex Pharmaceuticals entered into an exclusive commercialization agreement with CStone Pharmaceuticals for Sugemalimab, a fully human anti–PD-L1 monoclonal antibody, covering all approved and future indications in Australia and New Zealand. The agreement includes potential commercialization across stage III and IV non-small cell lung cancer, gastric cancer, esophageal squamous cell carcinoma, and extranodal NK/T-cell lymphoma, subject to regulatory approval by Australia’s Therapeutic Goods Administration.
VXA-222

VERAXA Biotech announced the advancement of bispecific ADC (bsADC) program VXA-222, following successful achievement of a key technical milestone in its alliance with OmniAb. The program is moving into its next collaboration phase with OmniAb’s discovery work successfully concluded. VXA-222 utilizes an "AND-gate" logic to address two different target antigens present on solid tumors with one molecule.
Additional Updates

The company appointed Amechi Nwachuku to the newly-created position of Executive Vice President and Chief Operating Officer, primarily responsible for managing the strategy, operations and commercial maximization of xPloration.
OmniAb will host an Investor and Analyst Day on October 6, 2026 at its corporate headquarters in Emeryville, CA. The agenda for the day will include presentations by management, panel discussions, and a lab tour for those attending in-person. For additional information and participation details, please visit.
Conference Call and Webcast

OmniAb management will host a conference call with accompanying slides today beginning at 4:30 p.m. ET (1:30 p.m. PT) to discuss this announcement and answer questions. To participate via telephone, please dial (833) 461-5787 using the conference ID 545137839. Slides, as well as the live and replay webcast, are available here.

(Press release, OmniAb, AUG 6, 2026, View Source [SID1234669837])

On August 6, 2026 Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, reported the first participant has been dosed in a Phase 1 clinical trial evaluating the safety and efficacy of DISP-10 in adult participants with advanced gastrointestinal (GI) cancers, including colorectal cancer, gastric adenocarcinoma, esophageal adenocarcinoma, and gastroesophageal adenocarcinoma. The participant was treated with both DV-10 and ide-cel components of DISP-10 and completed the protocol-defined dose-limiting toxicity (DLT) evaluation period. Additionally, DISP-10 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced GI cancers. DISP-10 is a novel, investigational therapy designed to address key challenges in the treatment of solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Initiating this trial represents a meaningful step forward for patients with advanced GI cancers, reinforced by the FDA’s Fast Track designation for DISP-10," said Mauro Avanzi, M.D., Ph.D., Chief Medical Officer of Dispatch. "We look forward to advancing this study as we work to overcome the longstanding limitations of treating solid tumors with immunotherapy, including lack of a safe and homogeneously expressed target antigen, a narrow therapeutic window, and an inhibitory tumor microenvironment. DISP-10 aims to address these barriers with our novel approach."

DISP-10 consists of two components. The first component, DV-10, is a tumor-specific virus engineered to deliver a modified B cell maturation antigen (dBCMA), along with IL-18 and CXCL9, to "paint" a synthetic antigen onto tumor cells, remodel the tumor microenvironment to support T cell function, and help enhance T cell trafficking into tumors. The second component is ide-cel, Bristol Myers Squibb’s BCMA-directed CAR T cell therapy approved in the U.S.* By leveraging components with significant clinical experience, Dispatch aims to proceed rapidly through clinical development and ultimately bring a major advancement and option to patients suffering from advanced GI cancers, including colorectal cancer, which currently is the leading cause of cancer death among people under age 50.1

"Patients with advanced GI cancers can face a challenging prognosis, often measured in a handful of months with limited treatment options beyond chemotherapy," said Marwan Fakih, M.D., Division Chief, GI Medical Oncology and Deputy Director, City of Hope Comprehensive Cancer Center. "There is a clear need for new approaches, and the initiation of this study with DISP-10 is an important step toward exploring a novel strategy that may expand the reach of immunotherapy treatments for patients."

The first-in-human, Phase 1, multicenter, open-label clinical study is designed to evaluate the safety, tolerability, and activity of DISP-10. The FDA’s Fast Track designation is intended to accelerate the development and review of investigational therapies that have demonstrated their potential to address serious conditions with unmet medical need. The designation enables more frequent engagement with the FDA and may allow for rolling review and other mechanisms to expedite the regulatory process.

*Ide-cel has not been studied and is not approved for use in solid tumors.

(Press release, Dispatch Bio, AUG 6, 2026, View Source [SID1234669836])

On August 6, 2026 TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, reported financial results for the quarter ended June 30, 2026, and provided an operational update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We delivered a second quarter marked by year-over-year and strong sequential growth. We continued strengthening our foundation to drive future expansion and adoption of the TriNav platform, and generated clinical evidence that demonstrates and validates the value of our technology," said Mary Szela, President and Chief Executive Officer of TriSalus. "We also wanted to acknowledge the Centers for Medicare and Medicaid Services ("CMS") on the recent establishment of a G-code that extends reimbursement for vascular embolization procedures with the use of a pressure-generating catheter into the physician office-based lab site of service. We look forward to maintaining an active dialogue with CMS as their team finalizes the reimbursement rate in the coming months.

We anticipate seeing further growth in the back half of the year and beyond as our sales team continues to ramp their efforts. We believe the long term growth opportunity for our PEDD platform remains substantial, and see an exciting pathway ahead."

Highlights for Second Quarter 2026 and Recent Weeks

Hosted virtual KOL event featuring a discussion around the new real-world evidence for PEDD in liver cancer.
Submitted for publication data from the PEDIR study, a multi-center, randomized trial conducted at Massachusetts General Hospital evaluating tumor-to-normal ratio in hepatocellular carcinoma and hypovascular tumors.
Financial Results for Q2 2026

Revenue from the sale of the TriNav system was $11.4 million for the three months ended June 30, 2026, which was relatively consistent with the prior comparative period with an increase of 1.7% compared to the same period in 2025.
Gross margins were 86.8% for the three months ended June 30, 2026, compared to 83.9% for the same period in 2025. The year-over-year increase in gross margin was primarily due to a reduction in cost per TriNav unit.
Operating losses were $9.8 million for the three months ended June 30, 2026, compared to losses of $7.3 million for the same period in 2025. The increase in operating losses was primarily driven by higher sales and marketing expenses related to our investment in marketing and our sales organization expansion, partially offset by improved gross margins, lower research and development and lower general and administrative expenses.
Net loss available to common stockholders was $9.2 million for three months ended June 30, 2026, compared to a net loss of $9.0 million for the same period in 2025. The current period includes $1.6 million of non-cash net gains related to changes in the fair value of various derivatives for the three months ended June 30, 2026, compared to net gains of $0.4 million for the same period in 2025. The basic and diluted loss per share for three months ended June 30, 2026 was $0.16, compared to $0.27 for the same period in 2025.
The non-GAAP measure of adjusted EBITDA is shown in the table below as the Company believes it is an important measure of performance. Adjusted EBITDA losses were $7.1 million for the three months ended June 30, 2026, compared to losses of $5.3 million for the same period in 2025. The increase in adjusted EBITDA losses were primarily driven by increased sales and marketing expenses, partially offset by improved gross margins, lower research and development and lower general and administrative expenses.
On June 30, 2026, cash and cash equivalents totaled $46.3 million. The Company raised $46.0 million in gross proceeds in the first quarter from an equity offering. The Company believes that these proceeds provide sufficient cash runway to fully fund commercial expansion and pipeline development.
2026 Financial Guidance

The Company is maintaining its full-year 2026 revenue guidance of $54 million to $57 million, consistent with the range set in the first quarter and representing growth of 19% to 26% compared to full year 2025.

Conference Call & Webcast

The Company will host a conference call and webcast today at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2026. Parties interested in participating by phone should register using the online form on our investor relations website. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. The event will also be webcast live on the investor relations section of TriSalus’ website. A replay will also be available on the website following the event.

(Press release, TriSalus Life Sciences, AUG 6, 2026, View Source [SID1234669835])

On August 6, 2026 Senhwa Biosciences, Inc. (TPEx: 6492) reported that the Taiwan Food and Drug Administration (TFDA) has cleared the Company’s multicenter Phase 1b/2a clinical trial evaluating its investigational drug pidnarulex (CX-5461) in combination with a marketed PD-1 immune checkpoint inhibitor. The TFDA clearance follows clearance by the U.S. Food and Drug Administration (FDA) in June 2026, enabling the study to proceed in both Taiwan and the United States. This marks an important step in the development of CX-5461 from a DNA-targeting drug candidate into a potential immuno-oncology combination platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1b/2a study is designed to assess the safety, tolerability, and preliminary antitumor activity of the combination in patients with advanced solid tumors. The study will enroll patients with pancreatic cancer, colorectal cancer, and melanoma, including patients whose disease has developed resistance to prior immune checkpoint inhibitor therapy—settings in which effective treatment options remain limited.

PD-1 and PD-L1 immune checkpoint inhibitors have transformed cancer care over the past decade. However, a substantial proportion of patients either do not respond initially or eventually develop resistance. In many so-called immune-cold tumors, limited immune-cell infiltration, insufficient antigen presentation, and an immunosuppressive tumor microenvironment can prevent the immune system from mounting an effective response, even when the PD-1 pathway is blocked. Overcoming these barriers and extending the reach of existing checkpoint therapies have therefore become central priorities in immuno-oncology research.

Pidnarulex (CX-5461) is Senhwa’s first-in-class investigational agent designed to induce DNA replication stress and DNA damage responses in cancer cells. Emerging research suggests that these mechanisms may not only directly impair tumor-cell survival but also promote immunogenic cell death, activate innate immune signaling, and increase immune activity within the tumor microenvironment. These potential effects provide the scientific rationale for evaluating whether CX-5461 can sensitize tumors to PD-1 blockade.

The study will investigate whether CX-5461 can favorably alter the tumor immune microenvironment, increase immune-cell infiltration and antigen presentation, and make immune-cold tumors more recognizable and vulnerable to immune attack. In patients whose disease has become resistant to immune checkpoint inhibition, the study will also explore whether the combination can restore antitumor immune activity. These potential effects remain clinical hypotheses and have not yet been established in patients.

The clinical program also reflects a broader shift across the biopharmaceutical industry. As immune checkpoint inhibitors become established backbones of cancer treatment, research and business development are increasingly focused on complementary agents that may broaden or deepen responses to existing PD-1 therapies, particularly in immune-cold and treatment-resistant tumors. Under Senhwa’s collaboration model, a global pharmaceutical company is supplying the marketed PD-1 inhibitor, while Senhwa leads the global and regulatory activities for the study.

Advancing a first-in-human combination study with a marketed immunotherapy, in collaboration with an experienced global pharmaceutical company, provides an internationally aligned framework for evaluating CX-5461 as a potential combination partner. Together with regulatory clearance in both the United States and Taiwan, the collaboration may increase the global visibility of CX-5461 and support future clinical development and partnering opportunities.

The strategic significance of the trial extends beyond a single combination regimen. If clinical data support the safety, immune-sensitizing activity, and preliminary efficacy of CX-5461, the asset could potentially be evaluated with additional PD-1 or PD-L1 therapies, in other tumor types, and alongside modalities such as antibody-drug conjugates, radiotherapy, and photodynamic therapy. This could position CX-5461 as a platform asset with potential applications across multiple cancers, products, and treatment modalities.

Senhwa will continue to advance study activation and patient enrollment and will use emerging safety, pharmacologic, efficacy, and biomarker data to identify the patient populations and development strategies most likely to benefit. The Company cautions that this is an early-stage clinical trial primarily intended to evaluate safety, tolerability, and preliminary efficacy. Whether CX-5461 can improve responses to PD-1 therapy, remodel the tumor immune microenvironment, or help overcome acquired resistance must be established through clinical data.

(Press release, Senhwa Biosciences, AUG 6, 2026, View Source [SID1234669834])